$16.93
-1.5%Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
No analyst price targets available for hql.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
During the last 12 months, insiders have purchased $134K and sold $2.53M worth of HQL shares, resulting in $2.40M of net selling activity.
0
0.00
0
0.00
+0
+$0
7.9K
133.75K
0
0.00
+134K
+$134K
0
0.00
131.0K
1.85M
-1.8M
-$1.85M
0
0.00
48.9K
683.46K
-683K
-$683K
Pittard Christian
Director
$134K
Saba Capital Management, L.P.
10 Percent Owner
$2.53M
Strong bearish signal with $2.40M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
Continue your HQL research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.